



Paul M. Rivard discusses the Myriad case in the San Francisco Daily Journal, Thomson Reuters, BioWorld Today, Boston Business Journal, Managing Intellectual Property and Chemical & Engineering News

April 17, 2013

Mr. Rivard discusses the Supreme Court's oral argument in *Association for Molecular Pathology et al. v. Myriad Genetics Inc. et al.* in a *San Francisco Daily Journal* article titled, "Human gene patents, biotech industry face Supreme Court scrutiny" (subscription required).

He also discusses the case and its implications in a *Thomson Reuters* article titled, "Justices appear to take middle ground on human gene patents," a *BioWorld Today* article titled, "Supreme Court Grapples With Science of DNA Claims" (subscription required), a *Boston Business Journal* article titled, "Patent attorney predicts middle path in Myriad decision," a *Managing Intellectual Property* article titled, "Reading the tea leaves from Myriad" (subscription required), and a *Chemical & Engineering News* article titled, "Court Reviews Genetic Patents."

Posted: April 12, 2013